What is NDC 50474-350?

50474-350 is the product NDC for Kygevvi, Doxecitine 2 g/1; Doxribtimine 2 g/1 powder, for solution, listed with the FDA by UCB, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Kygevvi (Doxecitine and doxribtimine).

UCB, Inc., NDC labeler code 50474. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Kygevvi?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Kygevvi NDC 50474-350 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)50474-350Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50474-0350Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50474-350-30	50474035030	30 PACKET in 1 CARTON (50474-350-30) / 1 POWDER, FOR SOLUTION in 1 PACKET (50474-350-01)Marketed from Mar 1, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Kygevvi
Generic name (nonproprietary): doxecitine and doxribtimine
Active ingredients: Doxecitine — 2 g/1Doxribtimine — 2 g/1
Dosage form: Powder, For solution
Route: Oral
Labeler: UCB, Inc.NDC labeler code 50474
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 219792
Marketing start: Mar 1, 2026
Listing expires: Dec 31, 2026
Identifiers: Product ID 50474-350_433f8057-35f8-f7e8-e063-6294a90a3ffdSPL ID 433f8057-35f8-f7e8-e063-6294a90a3ffdSPL set ID 7d5ce670-9314-4fd7-8b0a-1447910dcf9eRxCUI 2737535, 2737541UNII 0W860991D6, VC2W18DGKR

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450474035030 followed by a unit qualifier and the quantity

Package 50474-0350-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 10, 2025.

Indications (excerpt from the label)

KYGEVVI is indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. KYGEVVI is a combination of doxecitine and doxribtimine, both pyrimidine nucleosides, indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 50474-350

What is NDC 50474-350?: 50474-350 is the product NDC for Kygevvi, Doxecitine 2 g/1; Doxribtimine 2 g/1 powder, for solution, listed with the FDA by UCB, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Kygevvi (Doxecitine and doxribtimine).
What is the active ingredient?: Doxecitine, Doxribtimine.
Who is the labeler?: UCB, Inc., NDC labeler code 50474. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Kygevvi?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Kygevvi (Doxecitine and doxribtimine) NDC 50474-350